Market news

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Key TakeawaysConference Pop: Arcutis Biotherapeutics stock jumped 11. 19% on September 16, closing at $26.

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up roughly 16% over the past 3 months. The company, which focuses on dermatological treatments such as its lead product ZORYVE, now carries a market value of about US$3.16b and recently closed at US$24.87 as of 25 August 2026. Looking at the bigger picture, Arcutis Biotherapeutics has seen mixed...

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant...

Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.

Moby summary of Arcutis Biotherapeutics, Inc.'s Q2 2026 earnings call

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Arcutis Biotherapeutics Inc (ARQT) reports strong Q2 2026 results with record revenues, FDA approvals, and a raised full-year outlook.

Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications. The company generated net income o

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growthCompany raising 2026 full-year net product sales guidance to $525 million–$540 millionReceived approval to expand the indication for ZORYVE cream 0.3% for the topical treatment of plaque psoriasis to children down to the age of 2, the seventh FDA approval in four yearsFDA accepted sNDA for ZORYVE cream 0

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

Arcutis Biotherapeutics stock has delivered a very strong 176.6% return over the past three years, yet the broader valuation checks currently suggest it does not stand out as obviously expensive or obviously cheap. With the shares last closing at US$27.99 and the stock screening as "about right" on market multiples, investors are weighing how much of that past return is already reflected in the price. The 176.6% three year return highlights how strongly Arcutis Biotherapeutics has rewarded...

Arcutis Biotherapeutics (ARQT) is back in focus as Wall Street looks ahead to its June 2026 quarter earnings report on August 5, with expectations centered on higher earnings and revenue. See our latest analysis for Arcutis Biotherapeutics. At a recent share price of $27.99, Arcutis Biotherapeutics has seen firm momentum in the near term, with a 30 day share price return of 6.75% and a 90 day gain of 19.87%, set against a year to date share price return that is slightly lower and a very...

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tipranks Press Release.

Chris Peetz Arcutis Expands Board of Directors with Appointment of Chris Peetz WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher “Chris” Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026. “We are delighted to welcome Chris Peetz to our Board of Directors at a pivota

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day. A live webcast of the